Alzheimer’s disease is a devastating condition that affects the brain, causing severe memory loss.
Researchers have been searching for effective treatments to slow down or halt the progression of the disease for many years.
TB006 is an investigational drug currently being evaluated for its potential effects on symptoms of Alzheimer's disease.
This investigational treatment is available at our clinic through the Expanded Access Program (EAP), a program authorized by the FDA and carefully regulated to ensure patient safety and compliance with medical standards.
Here, we explain what TB006 Alzheimer is and what this investigational treatment may mean for patients and caregivers. TB006 is experimental and still undergoing clinical testing.
TB006 is an investigational drug that may reduce the buildup of amyloid plaques and neuroinflammation in the brain.
Amyloid plaques are predominantly made from proteins called “beta-amyloid” that clump together in the brains of people with Alzheimer’s.
The plaques disrupt communication between the brain cells (neurons) and cause inflammation, which leads to cognitive symptoms like memory loss.
By stopping the beta-amyloid proteins from clumping together to form plaques, TB006 may potentially improve the symptoms of Alzheimer's.
This could allow neurons to communicate more normally, which might improve cognition.
TB006 works by binding to a protein called Galectin-3, found in abnormally high levels in the brains of people with Alzheimer’s disease.
Galectin-3 binds to beta-amyloids, acting as a glue that causes these proteins to clump together and form amyloid plaques—but Galectin-3 cannot bind to TB006 and beta-amyloid at the same time.
By binding to Galectin-3, TB006 may stop Galectin-3 from acting as a glue.
By doing so, TB006 may potentially:
TB006 is considered a potential investigational treatment for Alzheimer’s disease (AD) for several reasons:
We are proud to announce that Universal Neurological Care is the first in Northeast Florida to infuse TB006 into an Alzheimer's patient.
This is a milestone for our clinic as we explore investigational options for people living with Alzheimer's disease.
Our commitment to exploring investigational treatment options is at the core of our mission to improve the lives of people affected by neurological disorders.
Please contact our clinic for information about investigational TB006 and the Expanded Access Program.
Stay tuned for more updates on TB006 and other developments in neurological care.
Q: What are the results of TB006?
A: TB006 is an investigational drug. Early clinical studies are currently ongoing to evaluate its potential effects on memory and cognitive function. Because it is investigational, its safety and effectiveness have not yet been established.
Q: What is Galectin-3 in Alzheimer’s disease?
A: Galectin-3 is a protein that acts as a glue, causing beta-amyloid proteins to clump together in the brain as plaques. TB006 is designed to target Galectin-3, which may prevent it from sticking these other proteins together.
Q: Is TB006 safe?
A: Because TB006 is investigational, its safety and effectiveness have not yet been established.
TB006 is an investigational drug. Early clinical studies are currently ongoing to evaluate its potential effects on memory and cognitive function.
If you or a loved one is affected by Alzheimer's disease and is interested in learning more about TB006, please contact our clinic. Our medical team can discuss eligibility for this investigational treatment through the Expanded Access Program (EAP), which is authorized by the FDA and carefully regulated.
Universal Neurological Care is here to provide information, support, and guidance as you navigate this challenging journey.
